Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors

Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has offered unpreced...

Ausführliche Beschreibung